Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Finnigan SR"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sankaran H; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Finnigan SR; Clinical Investigations Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Best AF; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Seibel NL; Clinical Investigations Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Publikováno v:
Cancer [Cancer] 2022 Nov 01; Vol. 128 (21), pp. 3843-3849. Date of Electronic Publication: 2022 Sep 12.
Autor:
Chihara D; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: dchihara@mdanderson.org., Lin R; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Flowers CR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Finnigan SR; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Cordes LM; Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Fukuda Y; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Huang EP; Biometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Rubinstein LV; Biometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ivy SP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Takebe N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: takeben@mail.nih.gov.
Publikováno v:
Lancet (London, England) [Lancet] 2022 Aug 13; Vol. 400 (10351), pp. 512-521.
Autor:
Chihara D; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.; Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MD., Huang EP; Biometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD., Finnigan SR; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD., Cordes LM; Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD., Skorupan N; Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MD., Fukuda Y; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD., Rubinstein LV; Biometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD., Ivy SP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD., Nastoupil LJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Flowers CR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Takebe N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Jun 10; Vol. 40 (17), pp. 1949-1957. Date of Electronic Publication: 2022 Mar 09.
Autor:
Abrams JS; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD 20852, USA. abramsj@mail.nih.gov, Mooney MM, Zwiebel JA, Korn EL, Friedman SH, Finnigan SR, Schettino PR, Denicoff AM, Kruhm MG, Montello M, Misra RR, Ansher SS, DiPiazza KJ, Souhan EM, Wickerham DL, Giantonio BJ, O'Donnell RT, Sullivan DM, Soto NI, Fleming GF, Prindiville SA, Petryshyn RA, Hautala JA, Grad O, Zuckerman BL, Meyer RM, Yao JC, Baker LA, Buckner JC, Hortobagyi GN, Doroshow JH
Publikováno v:
Journal of the National Cancer Institute [J Natl Cancer Inst] 2013 Jul 03; Vol. 105 (13), pp. 954-9. Date of Electronic Publication: 2013 Jun 17.